Raises full-year 2026 total global revenue guidance to approximately $1 billion, from approximately $950 million
Raises full-year 2026 BRIUMVI U.S. net product revenue guidance to approximately $915–920 million, from
CONFERENCE CALL TO BE HELD MONDAY, NOVEMBER 9, 2026, AT 8:30 AM ET
TG Therapeutics, Inc. (NASDAQ:TGTX), today announced that a conference call will be held, Monday, November 9, 2026, at 8:30 AM ET to discuss results
First reported clinical evaluation of an allogeneic CD19-directed CAR T-cell therapy in progressive MS demonstrated an encouraging preliminary safety profile with no high-grade CAR-T associated toxicities
Seven-year BRIUMVI data demonstrate sustained disease control, with approximately 88% of participants remaining free from confirmed disability progression after 7 years of continuous treatment
Phase 1 subcutaneous
BRIUMVI was associated with a lower risk of 24-week confirmed disability progression and lower annualized relapse rates (ARRs) over five years compared with ocrelizumab and ofatumumab
TG Therapeutics, Inc.
Late-breaking oral presentation will highlight initial clinical results evaluating azer-cel, an allogeneic "off-the-shelf" CD19-directed CAR T-cell therapy, in patients with progressive multiple
NEW YORK, Sept. 28, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of TG Therapeutics, Inc. (NASDAQ:TGTX) breached their fiduciary duties
AUSTIN, Texas, Sept. 10, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Today's multiple sclerosis treatments can slow down disease progression, but none of them halt it outright, and none give back the
NEW YORK, Sept. 10, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the H.C. Wainwright 28th
NEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the Cantor Global
- First clinical biopsy evidence of direct cccDNA elimination from ongoing Phase 1 ELIMINATE-B trial; PBGENE-HBV treatment led to a 1-log reduction in cccDNA with <1% remaining -
- In late-breaking data at EASL,
Second quarter 2026 total global revenue of approximately $240 million, including BRIUMVI U.S. net product revenue of approximately $228 million Raises full year 2026 total global revenue target to approximately $950
NEW YORK, July 29, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced that a conference call will be held, Monday, August 3, 2026, at 8:30 AM ET to discuss results for the second quarter
NEW YORK, July 21, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of TG Therapeutics, Inc. (NASDAQ:TGTX) breached their fiduciary duties
NEW YORK, July 16, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of TG Therapeutics, Inc. (NASDAQ:TGTX) breached their fiduciary
